According to DelveInsight, the Surgical Site Infections pipeline involves over 5 leading companies actively developing more than 5 therapeutic candidates for the treatment of Surgical Site Infections.
Surgical Site Infections Overview:
A surgical site infection (SSI) is an infection that occurs at the location of a surgical procedure. SSIs can vary in severity, ranging from minor infections affecting only the skin to more serious cases involving deeper tissues, organs, or implanted medical devices. The CDC provides guidelines and resources to help healthcare professionals prevent SSIs and educate the public on reducing their risk.
Symptoms usually appear within 5 to 7 days after surgery but can develop up to three weeks later, especially when a prosthetic implant is involved. Common indicators include spreading redness (erythema), localized pain, pus or discharge from the wound, and persistent fever (pyrexia).
Request for a detailed insights report on Surgical Site Infections pipeline insights
"Surgical Site Infections Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Surgical Site Infections Therapeutics Market.
Key Takeaways from the Surgical Site Infections Pipeline Report
-
DelveInsight’s Surgical Site Infections (SSI) pipeline report highlights a developing landscape, with over 5 active companies working on more than 5 therapeutic candidates for SSI treatment.
-
Key players—including Destiny Pharma plc, POLYPID, Exoxemis, Covira Surgical, Eupraxia Pharmaceuticals, Sonoran Biosciences, and others—are exploring new drugs to enhance the SSI treatment landscape. Notable pipeline therapies in various stages of development include XF-73, D-PLEX100, and others.
-
In March 2025, PolyPid Ltd. announced the successful completion of patient enrollment for its SHIELD II Phase 3 trial, which is assessing the efficacy of D-PLEX₁₀₀, a novel therapy designed to prevent SSIs in patients undergoing abdominal colorectal surgeries with large incisions.
-
Additionally, a study published in March 2024 showed that implementing a straightforward pre-surgical infection prevention protocol significantly reduced severe post-surgical infections, highlighting the critical role of standardized preventive measures in surgical care.
Surgical Site Infections Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Surgical Site Infections Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Surgical Site Infections treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Surgical Site Infections market.
Download our free sample page report on Surgical Site Infections pipeline insights
Surgical Site Infections Emerging Drugs
-
XF-73: Destiny Pharma plc
-
D-PLEX100: POLYPID
Surgical Site Infections Companies
Over five leading companies are actively working on therapies for Surgical Site Infections (SSIs), with POLYPID having a drug candidate that has reached the most advanced stage of development, Phase III.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Surgical Site Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Surgical Site Infections Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Surgical Site Infections Therapies and Key Companies: Surgical Site Infections Clinical Trials and advancements
Surgical Site Infections Pipeline Therapeutic Assessment
• Surgical Site Infections Assessment by Product Type
• Surgical Site Infections By Stage
• Surgical Site Infections Assessment by Route of Administration
• Surgical Site Infections Assessment by Molecule Type
Download Surgical Site Infections Sample report to know in detail about the Surgical Site Infections treatment market @ Surgical Site Infections Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Surgical Site Infections Current Treatment Patterns
4. Surgical Site Infections - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Surgical Site Infections Late-Stage Products (Phase-III)
7. Surgical Site Infections Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Surgical Site Infections Discontinued Products
13. Surgical Site Infections Product Profiles
14. Surgical Site Infections Key Companies
15. Surgical Site Infections Key Products
16. Dormant and Discontinued Products
17. Surgical Site Infections Unmet Needs
18. Surgical Site Infections Future Perspectives
19. Surgical Site Infections Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Surgical Site Infections Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
